Combination ofTripterygium wilfordiiHook F and angiotensin receptor blocker synergistically reduces excretion of urinary podocytes in patients with type 2 diabetic kidney disease

Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin

(2012) M. Hara et al.   DIABETOLOGIA

Relationship between Urinary Podocytes and Kidney Diseases

(2012) Dong Sun et al.   RENAL FAILURE

Podocytopathy in Diabetes: A Metabolic and Endocrine Disorder

(2011) Ana Diez-Sampedro et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Podocyte Detachment in Type 2 Diabetic Nephropathy

(2011) E. Jennifer Weil et al.   AMERICAN JOURNAL OF NEPHROLOGY

Treatment of the post-ischaemic inflammatory syndrome of diabetic nephropathy

(2010) K.J. Kelly et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Treatment of db/db diabetic mice with triptolide: a novel therapy for diabetic nephropathy

(2010) Q. Gao et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Normalization of obesity-associated insulin resistance through immunotherapy

(2009) Shawn Winer et al.   NATURE MEDICINE

Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?

(2009) Roger M. Mason   Journal of Cell Communication and Signaling

Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker

(2008) Gang Wang et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The Role of Osteopontin in the Development of Albuminuria

(2008) J. Lorenzen et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY